Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONA: NST-4016 in NASH
NCT04052516Phase 2Completed
- Sponsor
- NorthSea Therapeutics
- Start
- Jul 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of icosabutate in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by NorthSea Therapeutics. Primary endpoint: Percentage of Patients With Resolution of NASH Without Worsening of Fibrosis at 52 weeks. Started Jul 2019; status: completed.
02
Drugs
icosabutate
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04052516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052516.